Article
Dasatinib induces DNA damage and activates DNA repair pathways leading to senescence in non-small cell lung cancer cell lines with kinase-inactivating BRAF mutations.
Oncotarget - 5 Jan 2016
Peng Shaohua, Sen Banibrata, Mazumdar Tuhina, Byers Lauren A, Diao Lixia, Wang Jing, Tong Pan, Giri Uma, Heymach John V, Kadara Humam N, Johnson Faye M
Abstract excerpt
Improved therapies are greatly needed for non-small cell lung cancer (NSCLC) that does not harbor targetable kinase mutations or translocations. We previously demonstrated that NSCLC cells that harbor kinase-inactivating BRAF mutations (KIBRAF) undergo senescence when treated with the multitargeted kinase inhibitor dasatinib. Similarly, treatment with dasatinib resulted in a profound and durable response in a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.